Lv1
70 积分 2022-11-22 加入
Nonclinical Safety Profiles of mRNA Therapeutics Comprising Unmodified or N1-Methyl-Pseudouridine-Modified Nucleosides Are Similar Following Repeated Administration
2个月前
已完结
Structural basis for chaperone-guided assembly of RNA-induced silencing complex
2个月前
已完结
The different functions of short and long thymic stromal lymphopoietin isoforms in autophagy-mediated asthmatic airway inflammation and remodeling
3个月前
已完结
In vivo epigenome editing reduces circulating lipids and attenuates atherosclerosis in mice
4个月前
已完结
Improve the efficiency of gene silencing through 2′-O-methyl modification of the bases in siRNA terminus
4个月前
已完结
Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosis
5个月前
已完结
Enhancing RNAi activity through 4′-O-hexadecyl-2′-deoxythymidine modification in the passenger Strand
6个月前
已完结
Oligonucleotide Therapeutics Patenting: Strategies for Success
9个月前
已完结
Lipoprotein(a) as a multisystem disease risk factor: Clinical implications and the Dawn of RNA-based therapeutics
10个月前
已完结
Nonclinical Pharmacokinetics Study of OLX702A-075-16,N-Acetylgalactosamine Conjugated Asymmetric Small Interfering RNA (GalNAc-asiRNA)
1年前
已完结
皖公网安备34019202002308
